Two of33 prostatic tumourxenografts were established and passaged. Testosterone supplementation did not improve tumour take rates. The histological grade of the parent tumour was the principal factor affecting xenograft survival. Preliminary studies on established tumour xenografts suggest that their value lies in the study of tumour biology, and that they have no direct therapeutic application at present.
Introduction
The demonstration by Huggins & Hodges (1941) that prostatic cancer responded to hormone manipulation has remained the mainstay of the therapy of metastatic disease. However, new models are urgently required to investigate the phenomenon of 'hormone escape' and hormone resistance. There are no entirely satisfactory animal tumour models available (Riverson & Silverman 1979) , and this preliminary study was undertaken to assess the feasibility ofgrowing human prostatic tumours in laboratory animals.
Methods
The 'nude' mouse has been shown to accept heterologous human tumours (Povlsen & Rygaard 1971 ). An alternative method of establishing human tumour xenografts is to prepare immune deprived mice according to the technique of Davies et al. (1969) . Human prostatic tumours were transplanted as 2 mm fragments into male nude and deprived mice. Transplants were placed subcutaneously in the flank, under the kidney capsule according to the method of Davies et al. (1966) , and subcutaneously into the ear pouch.
Testosterone and oestradiol were administered as pellet implants and cyproterone acetate was given as a subcutaneous injection in benzyl benzoate and caster oil. Plasma hormone levels of testosterone and oestradiol 17-P were measured in CBA/ca mice. The radioimmunoassay was performed at Wexham Park Hospital by arrangement with Organon Laboratories.
Arginase has been proposed as a potentially useful experimental indicator of prostatic function (Sandberg & Gaunt 1976) . The enzyme activity, expressed as micromoles of urea liberated per gram of tissue per minute, was estimated by Sandberg's modification of Schimke's method (Sandberg 1975) .
Results
Tumours from 33 patients were transplanted into a total of 60 male nude and deprived mice. Two xenografts, one derived from a primary tumour and the other from a lymph node metastasis, were established and passaged. The tumours persisted but showed no evidence of growth (Table 1) . Much of the material was obtained by transurethral resection, and the recovery of viable (but not necessarily malignant) tissue from 21 of 26 tumours (Table 2) suggests that this material is satisfactory provided that necrotic or burnt tissue is removed before transplantation. No autopsy material resulted in viable tissue being recovered. This was probably due to the time which elapsed between death and tumour transplantation. Okada et al. (1976) have suggested that the take rate of xenografts of benign prostatic hyperplastic and prostatic tumour can be improved by the use of testosterone supplementa-I Paper read to Sectionof Oncology, 9 April 1980. Accepted22 July 1980 0141-0768/80/100708-05/$01.00/0 © 1980 The RoyalSocietyof Medicine tion. We were unable to repeat this observation in respect of tumours, although the recovery of non-malignant tissue was improved (Table 3) . It can be seen from Figures 1 and 2 that implants of testosterone and oestradiol to CBA/ca mice resulted in markedly elevated and unphysiological plasma hormone levels compared with those of the deprived mice or the adult human male (Williams et al. 1978) . Several transplantation sites were examined for an effect on xenograft survival (Table 4) , but none provided better survival than the subcutaneous space, and there was no difference in xenograft survival between 'nude' and deprived mice. The most important factor which influenced graft survival was the histological grade of the parent tumour, such that only poorly or moderately differentiated tumours were recovered (Table 5 ).
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• Group I C Mice bearing The primary tumour xenograft (M27/78) had a poor take rate in passage (25%). During the period ofgrowth of the oestradiol treated tumours, their growth rate was apparently twice that of the control (Figure 6 ). Extreme caution must be employed in trying to interpret such limited data, but if this was a true reflection of tumour growth it suggests that oestrogensensitive cells have been lost during transplantation or growth, resulting in increased growth of hormone independent cells.
Arginase activity was demonstrated in both xenografts (Table 6) 5 ..........:......-,........,r---.,.-..,..-. 2.
6.9 Figure 6 . Tumour M27/78. Passage 1-oestradio125 mg between different passages of the same tumour. Testosterone and oestradiol both resulted in decline in arginase activity, but could not be directly correlated with the growth kinetics of the tumours. No histological effect was noted as a result of hormone treatment of xenografts. The xenografts remained histologically unchanged after 6 passages and their histological appearances compared well to the parent tumours. The karyotype of both tumours showed a human modal chromosomal distribution and both X and Y chromosomes were present. 
Discussion
Human tumour xenografts have been successfully grown in immunologically privileged sites, such as the anterior chambers of the rabbit eye, since the 1950s (Greene 1952) . Recently, the xenograft system has become easier to use with the description of the nude mouse and the preparation of the immune deprived mouse. However, hormone dependent tumours, notably breast, have been shown to be difficult to grow (S D Detrie 1978, personal communication), and published reports of successfully grafted human prostatic tumours are few (Mickey et al. 1977 , Sato et al. 1975 , Okada et al. 1976 ).
Our preliminary studies illustrate some of the difficulties of using the tumour xenograft system. The small number of tumours which can be grown, and their relatively poor differentiation, impose a high degree of selectivity on the tumours which can be studied. However, the two prostatic tumour xenografts investigated have been shown to be hormone insensitive, at least as far as their growth kinetics are concerned. However, from a clinical point of view, these are the tumours which pose the greatest treatment problems.
The assessment of xenografts by growth kinetic studies is a relatively crude assessment of tumour behaviour. Such experiments are difficult to control and interpret, particularly where the take rate of passaged tumours is low. In the absence of a better biochemical parameter, prostatic arginase would seem to be worth pursuing as a parameter of prostatic function.
We conclude from our preliminary studies that the value of prostatic tumour xenografts in the investigation of function must be confined to the study of tumour biology, the effect of chemotherapeutic agents and the hormonal background to prostatic cancer. Attempts to use this model to predict clinical response are unrealistic at the present time.
